Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world's most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogen...
Saved in:
| Published in: | Current pharmaceutical biotechnology Vol. 24; no. 2; p. 238 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
01.01.2023
|
| Subjects: | |
| ISSN: | 1873-4316, 1873-4316 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world's most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases. |
|---|---|
| AbstractList | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world's most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world's most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world's most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases. |
| Author | Acco, Alexandra Corso, Claudia Rita Stipp, Maria Carolina |
| Author_xml | – sequence: 1 givenname: Maria Carolina surname: Stipp fullname: Stipp, Maria Carolina organization: Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, Brazil – sequence: 2 givenname: Claudia Rita surname: Corso fullname: Corso, Claudia Rita organization: Pelé Little Prince Research Institute (IPPP), Curitiba, Brazil – sequence: 3 givenname: Alexandra surname: Acco fullname: Acco, Alexandra organization: Department of Pharmacology, Federal University of Paraná (UFPR), Curitiba, Brazil |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35593354$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAYhC1URD_gLyCzsQTs147jsJVAoVKrLgWxRa79Rg3KF7Ez8O-JRJGY7oZHd6ebk0nTNkjIDWd3wBN5z4VOgXEGQikFwCRwLoTg_IzMuE5EJAVXk39-SubefzIGTGu4IFMRx6kQsZyRj3XdGRs8bQua7d7XTxFPadnQxx6NDzQzjcX-ga76tqbbtkI7VKanW7RH05S-pqGl4Yh0P-KhxibQZdf1rbHHS3JemMrj1UkX5G31vM9eo83uZZ0tN9EhZjpEWhopVSG4k4llscODFEnKjR23u0IKaRBBgkMnUoiFVg51AU7FYGSqhYEFuf3NHWu_BvQhr0tvsapMg-3gc1AqSXQqk2REr0_ocKjR5V1f1qb_zv_egB8WbWLk |
| CitedBy_id | crossref_primary_10_1007_s00044_024_03201_7 crossref_primary_10_1186_s13756_023_01361_6 crossref_primary_10_1038_s41598_025_86710_8 crossref_primary_10_1097_MD_0000000000042372 |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/1389201023666220421133311 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4316 |
| ExternalDocumentID | 35593354 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) grantid: 001 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grantid: 305787/2018-7, 430465/2018-1 |
| GroupedDBID | --- .5. 0R~ 29F 36B 4.4 53G 5GY AAEGP ABEEF ABJNI ACGFS ACITR ACIWK ACPRK ACZAY AENEX AFRAH AFUQM AGJNZ ALMA_UNASSIGNED_HOLDINGS ANTIV C1A CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P GH2 HZ~ IPNFZ KCGFV NPM O9- P2P RIG 7X8 ABMOS AFHZU AGQPQ |
| ID | FETCH-LOGICAL-b508t-84a446f31d47c05deb43791ac187df434aee242ded3925386de8f2d652a4983a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000943036100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1873-4316 |
| IngestDate | Wed Oct 01 12:28:49 EDT 2025 Thu Jan 02 22:52:57 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | COVID-19 SARS-CoV-2 mammary tumor cytokine storm chemotherapy drug interaction |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b508t-84a446f31d47c05deb43791ac187df434aee242ded3925386de8f2d652a4983a2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 35593354 |
| PQID | 2667789477 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2667789477 pubmed_primary_35593354 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current pharmaceutical biotechnology |
| PublicationTitleAlternate | Curr Pharm Biotechnol |
| PublicationYear | 2023 |
| SSID | ssj0020882 |
| Score | 2.3701124 |
| SecondaryResourceType | review_article |
| Snippet | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 238 |
| SubjectTerms | Breast Neoplasms - drug therapy COVID-19 Female Humans SARS-CoV-2 |
| Title | Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35593354 https://www.proquest.com/docview/2667789477 |
| Volume | 24 |
| WOSCitedRecordID | wos000943036100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEF61gBCXtrxDHxokxCkr4t211-aCQtqoHBJyCCi3aLMPKQdsiNNK-fedsR1yQkLqxTdb1ng8883OzPcxdhGyjvKuE3iIrOVKBMeNTR23sfR-ZgLxqVRiE3o4TCeTbNQcuJXNWOU6JlaB2hWWzsivMJFonWZK65vnF06qUdRdbSQ0PrJtiVCGvFpPXrsIguAjFVyplpxWvnfZOY0-Iwi_ov4cNYKFRPwuBLpuhNWajKK3kWaVcfqf__ddv7BPDdaEbu0c--yDzw_Y5agmq161YbzZvSrbcAmjDY316pBN7qoFyhKKAL37x7ufPMpgnsMtjbEvoUfusriG_qJ4gsFaZBcGnlaJ5-UTLAtAcAnj9SQ7dBv68iP20P817v3mjQ4DnyF8W_JUGSwag4yc0rYTOz8jEsPIWDSsC0oq4z1meucdgi0MoInzaRAuiYVRWSqNOGZbeZH7UwaJls7HUqQRMQ0Gh_Wpwadi3HGJt0nSYudri07Rz6l5YXJf_CmnG5u22En9WabPNSHHFDFTJmWszt5x91e2R4rx9SnKN7Yd8C_339mO_bucl4sflQPhdTga_AOClc21 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impacts+of+COVID-19+in+Breast+Cancer%3A+From+Molecular+Mechanism+to+the+Treatment+Approach&rft.jtitle=Current+pharmaceutical+biotechnology&rft.au=Stipp%2C+Maria+Carolina&rft.au=Corso%2C+Claudia+Rita&rft.au=Acco%2C+Alexandra&rft.date=2023-01-01&rft.issn=1873-4316&rft.eissn=1873-4316&rft.volume=24&rft.issue=2&rft.spage=238&rft_id=info:doi/10.2174%2F1389201023666220421133311&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-4316&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-4316&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-4316&client=summon |